Short Interest Surges to 21.83% as Coherus BioSciences, Inc. (CHRS) Faces Revenue Challenges

Yahoo FinanceSep 25 11:28 ET

Institutional Owners May Take Dramatic Actions as Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Recent 12% Drop Adds to One-year Losses

Yahoo FinanceSep 20 06:28 ET

Baird Maintains Coherus BioSciences(CHRS.US) With Buy Rating, Maintains Target Price $8

Moomoo NewsSep 16 20:31 ET · Ratings

Top Midday Decliners

MT NewswiresSep 16 14:09 ET

Truist Financial Maintains Coherus BioSciences(CHRS.US) With Buy Rating

Moomoo NewsSep 16 07:31 ET · Ratings

H.C. Wainwright Maintains Coherus BioSciences(CHRS.US) With Buy Rating, Maintains Target Price $12

Moomoo NewsSep 16 06:31 ET · Ratings